This work is licensed under a Creative Commons Attribution 4.0 International License.
Acromegalia and hypofisarian adenomas: a review of literature
Corresponding Author(s) : Luis Rafael Moscote-Salazar
Ciencia e Innovación en Salud,
Acromegaly is a condition that includes certain clinical manifestations caused by high serum levels of growth hormone that, in most cases, is due to the presence of pituitary adenomas. The early clinical suspicion of this entity and its timely diagnosis allows the treatment to generate high rates of remission of the disease. Growth hormone producers account for 10 to 25%, its unspecific clinical manifestations, added to the insidious behavior of the disease, lead to a delay in its diagnosis and treatment, in such a way that the suspicion of this condition at the beginning of the appearance of signs and symptoms is relevant to decrease its morbidity.
Download CitationEndnote/Zotero/Mendeley (RIS)
1. Practice E, Electronic R, Rapid P, Articles E. UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS. 2018;
2. Lake MG, Hospital USN. Pituitary Adenomas?: An Overview. Am Fam Physician. 2018;88(5):319–27.
3. Ben-shlomo A. Acromegaly. 2018;37(2008):101–22.
4. Bima C, Chiloiro S, Mormando M, Piacentini S, Bracaccia E, Giampietro A, et al. Expert Review of Endocrinology & Metabolism Understanding the effect of acromegaly on the human skeleton. 2016;6651(May).
5. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. 2017;(August):228–43.
6. Castaño L, Martínez I, Piscina D, Portillo N, Rica I. Adenomas hipofisarios?: Impacto clínico de los hallazgos moleculares. 2017;8:35–45.
7. Vilar L, Freitas C, Ruy V, Raissa L. Acromegaly?: clinical features at diagnosis. Pituitary. 2016;
8. Hossain B, Drake WM. Acromegaly. Medicine (Baltimore). 2017 Aug;45(8):480–3.
9. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am. 2008 Mar;37(1):101–22.
10. Marques P, Korbonits M. Genetic Aspects of Pituitary Adenomas. Endocrinol Metab Clin North Am. 2017 Jun;46(2):335–74.
11. Bima C, Chiloiro S, Mormando M, Piacentini S, Bracaccia E, Giampietro A, et al. Understanding the effect of acromegaly on the human skeleton. Expert Rev Endocrinol Metab. 2016 May;11(3):263–70.
12. Iglesias P, Rodríguez Berrocal V, Díez JJ. Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. Endocrine. 2018 Sep;61(3):407–21.
13. Sousa L, Isabelle T, Oliveira B De, Andre S, Lopes L, Augusto C, et al. Hearing Loss in Acromegaly - A Review. 2018;1–4.
14. Mayson SE, Snyder PJ. Silent Pituitary Adenomas. Endocrinol Metab Clin North Am. 2015 Mar;44(1):79–87.
15. Hong GK, Payne SC, Jane JA. Anatomy, Physiology, and Laboratory Evaluation of the Pituitary Gland. Otolaryngol Clin North Am. 2016 Feb;49(1):21–32.
16. Bagga V, Sinha S. Surgery for pituitary tumours. Surg. 2017 Oct;35(10):556–62.
17. Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer. 2015 Apr;22(2):169–77.
18. Zahr R, Fleseriu M. Updates in Diagnosis and Treatment of Acromegaly. 2018;(September):57–61.
19. Jane JA, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, et al. Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome. J Clin Endocrinol Metab. 2011 Sep;96(9):2732–40.
20. Cooper O, Greenman Y. Dopamine Agonists for Pituitary Adenomas. Front Endocrinol (Lausanne). 2018 Aug;9(August):1–8.
21. Kuhn E, Chanson P. Cabergoline in acromegaly. Pituitary. 2017 Feb;20(1):121–8.
22. Colao A, Bronstein MD, Freda P, Gu F, Shen C-C, Gadelha M, et al. Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. J Clin Endocrinol Metab. 2014 Mar;99(3):791–9.